HC Wainwright Expects Reduced Earnings for BridgeBio Pharma

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Research analysts at HC Wainwright lowered their Q3 2026 earnings per share estimates for BridgeBio Pharma in a research note issued to investors on Monday, July 13th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.38) for the quarter, down from their previous estimate of ($0.37). HC Wainwright has a “Buy” rating and a $120.00 price objective on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($2.30) per share. HC Wainwright also issued estimates for BridgeBio Pharma’s FY2026 earnings at ($1.50) EPS and Q1 2027 earnings at $0.11 EPS.

Other research analysts have also issued reports about the stock. Morgan Stanley upped their target price on shares of BridgeBio Pharma from $94.00 to $98.00 and gave the company an “overweight” rating in a report on Thursday, May 28th. Canaccord Genuity Group initiated coverage on shares of BridgeBio Pharma in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $104.00 price objective for the company. Royal Bank Of Canada assumed coverage on shares of BridgeBio Pharma in a research report on Thursday, April 9th. They issued an “outperform” rating and a $100.00 price objective for the company. Truist Financial upped their price objective on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Finally, Mizuho decreased their target price on shares of BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 16th. Twenty research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.63.

BridgeBio Pharma Trading Up 1.2%

BridgeBio Pharma stock opened at $84.09 on Wednesday. The stock has a 50-day moving average price of $70.31 and a 200 day moving average price of $72.18. BridgeBio Pharma has a 52 week low of $42.09 and a 52 week high of $93.42. The stock has a market cap of $16.47 billion, a PE ratio of -22.48 and a beta of 0.95.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.14). The firm had revenue of $194.51 million during the quarter, compared to the consensus estimate of $178.07 million. The firm’s revenue was up 66.8% on a year-over-year basis. During the same period last year, the business posted ($0.88) earnings per share.

Insider Activity

In other BridgeBio Pharma news, Director Jennifer E. Cook sold 148,589 shares of BridgeBio Pharma stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $88.54, for a total value of $13,156,070.06. Following the completion of the sale, the director owned 8,383 shares in the company, valued at $742,230.82. The trade was a 94.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Andrea Ellis sold 17,167 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $84.00, for a total transaction of $1,442,028.00. Following the transaction, the director directly owned 22,579 shares of the company’s stock, valued at approximately $1,896,636. This represents a 43.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 432,117 shares of company stock valued at $32,633,740 in the last three months. Company insiders own 14.23% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Harvest Fund Management Co. Ltd purchased a new stake in BridgeBio Pharma in the third quarter valued at approximately $34,000. Jones Financial Companies Lllp purchased a new position in BridgeBio Pharma during the first quarter worth approximately $35,000. Farther Finance Advisors LLC boosted its holdings in shares of BridgeBio Pharma by 91.4% in the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock valued at $39,000 after purchasing an additional 245 shares during the last quarter. Global Retirement Partners LLC boosted its holdings in shares of BridgeBio Pharma by 271.5% in the 4th quarter. Global Retirement Partners LLC now owns 509 shares of the company’s stock valued at $39,000 after purchasing an additional 372 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of BridgeBio Pharma in the 4th quarter valued at $41,000. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright raised several forward earnings estimates for BridgeBio Pharma, including FY2027 EPS to $2.19 from $2.12 and Q4 2027 EPS to $0.92 from $0.88, while keeping a Buy rating and $120 price target. Higher profit expectations and a still-bullish valuation view can support the stock. BridgeBio Pharma stock page
• Positive Sentiment: The stock also benefited from earlier research commentary noting that BridgeBio could be a relative winner from a Phase 3 failure in the biotech sector, which may have improved sentiment toward the name. Related article
• Neutral Sentiment: HC Wainwright trimmed near-term EPS estimates for Q3 2026, Q1 2027 and FY2026, reflecting some caution on shorter-term earnings, though the revisions were modest and did not change the firm’s Buy rating. BridgeBio Pharma stock page
• Negative Sentiment: Recent insider selling by directors Andrea Ellis and Jennifer E. Cook, including a large share sale by Cook, may create some pressure on investor confidence even though both transactions were made under pre-arranged 10b5-1 plans. Insider trading article

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.